2015 APPENDIX - CENTER OF NEUROLOGY TÜBINGEN - Hertie-Institut für klinische Hirnforschung
←
→
Transkription von Seiteninhalten
Wenn Ihr Browser die Seite nicht korrekt rendert, bitte, lesen Sie den Inhalt der Seite unten
CENTER OF NEUROLOGY
TÜBINGEN
Annual Report
2015
APPENDIX
Content 2
ANNUAL REPORT 2015
Appendix
UNIVERSITY HOSPITAL OF NEUROLOGY
DEPARTMENT OF NEUROLOGY AND STROKE
DEPARTMENT OF NEUROLOGY AND EPILEPTOLOGY
DEPARTMENT OF NEURODEGENERATIVE DISEASES
DEPARTMENT OF COGNITIVE NEUROLOGY
DEPARTMENT OF CELLULAR NEUROLOGY
INDEPENDENT RESEARCH GROUPS
PUBLICATIONS AND STUDENT TRAINING IN 2015
3
University
Hospital of
Neurology
Clinical Staff WARD 42 WARD 44
Ronja Bühler Andrea Albrecht
HEAD OF NURSING SERVICES Anja Hutter Karin Brunner
Gabriele Kern-Braun Ana-Maria Cheregi
Dr. Renate D. Fuhr Renate Maier Korneck Jessica Deile
(Head of Nursing Services) Bettina Mollenhauer Tobias Göttermann
Ilse Polack Kathrin Gray
Doris Stenske-Bader Ulrike Rein Susanne Grumann
(Deputy Head of Nursing Services) Iris Sadowski Carmen Haag
Sarah Schneider Frank Hauber
Adriana Hurcikova Ulrike Schweizer Marc-Sebastian Haug
(Division Manager, Ward 42/43/45) Julia Sieberichs Stefanie Herholz
Gudrun Siegl Regina Johner
Bärbel Hauger Birgit Weimar Eftimia Kalpakli
(Deputy Division Manager, Naemi Zimmermann Petra Kaschowitz
Ward 42/43/45) Luisa Biesinger
Ines Lange
Simone Ochieng WARD 43 Nina Melzer
(Deputy Division Manager, Samantha Mekanovic
Ward 42/43/45) Jane Buo Christine Moosmann
Meike Besser Birgit Moryson
Christine Reuter Önder Bilen Markus Müller
(Ward Manager, Ward 44) Friedhelm Chmell Petra Nipprasch
Annette Eisele Simone Ochieng
Annette Mögle Britta Eisemann Magdalena Rauch-Schmidt
(Deputy Ward Manager, Ward 44) Rebecca Fais Heidi Riescher
Maria Flohr Claudia Romeikat
Alice Hoffmann Thomas Rottmann
Eva Kern Mirjam Schäfer
Jürgen Kronmüller Johann Schmuck
Dorothe Pacholleck Tanja Striebich
Sina Westbomke Lothar Villinger
Stephanie Zanfardino Marlene Wamsler-Lutz
4
ANNUAL REPORT 2015
Angelika Weber INTENSIVE CARE/ CASE/OCCUPANCY
Gerda Weise STROKE UNIT MANAGEMENT
Eva Wener Buck
Dieter Zeller Andrea Albrecht Ulrich Braun
Ulrike Zimmermann Karin Brunner Silvia Clement
Jessica Deile Wilhelm Eissler
Tobias Göttermann Christina Tomschitz
WARD 45 Kathrin Gray
Susanne Grumann
Sigrid Baltes Carmen Haag TECHNICIANS
Johanna Eisele Frank Hauber
Isaac Emwinghare Marc-Sebastian Haug Anke Deutsch (EP)
Tatjana Graz Stefanie Herholz Evelyn Dubois (CFS Chemistry)
Werner Hansen Regina Johner Siegfried Ebner (CSF Chemistry)
Sigrid Herter Eftimia Kalpakli Renate Mahle (EEG Neurosonography)
Annika Hesse Petra Kaschowitz Yvonne Schütze
Michael Heymann Luisa Kramhöller Veronika Serwotka
Carolin Klebitz Ines Lange Elke Stransky
Beate Kloster Samantha Mekanovic Deborah Tünnerhoff-Barth
Olga Krämer Annette Mögle Nathalie Vetter (ENG Neurosono-
Stefanie Kurz Christine Moosmann graphy)
Andrea Langmann Birgit Moryson Kathrin Vohrer
Alisa Mansour-Tokovic Markus Müller Barbara Wörner (EEG)
Banu Sahin Nora Müller
Hans Jürg Scholpp Petra Nipprasch
Matthias Schroth Simone Ochieng SECRETARIES
Karola Schweinbenz Magdalena Rauch-Schmidt
Anja Siegle Christine Reuter Ina Baumeister
Lena Stengel Heidi Riescher Dr. Patricia Beck
Isabel Utsch Sellnow Claudia Romeikat Jutta Eymann
Mirjam Schäfer Dagmar Heller-Schmerold
Johann Schmuck Isolde Marterer
NURSING ASSISTANTS Annika Schneider-Kargbo Christine Riegraf
Gloria Sementilli Susanne Stimmler
Khuzame Allouch Tanja Striebich Diana Thomma
Tamazur Allouch Villinger Lothar Doris Wieder
Irina Amosenka Marlene Wamsler-Lutz
Luther Basa Angelika Weber
Roselyn Chin Gerda Weise MEDICAL DOCUMENTATION
Ludovie Dagmil Bettina Weisser
Joann Gallo Eva Wener Buck Sonja Brandner
Imad Kheireddine Dieter Zeller Christine Brick
Christopher Kübler Ulrike Zimmermann Horst Feuerbacher
Gabriele Layla Martina Pabst
Christin Matthes
Nikki Mortega
Emely Paul
Maritta Weipert
5
Department
of Neurology
and Stroke
Clinical and Scientific Staff SCIENTISTS/RESIDENTS
Dr. Asghar Abbasi (until 03/2015)
HEAD OF THE DEPARTMENT Dr. Paolo Belardinelli (since 04/2015)
Dr. Til Ole Bergmann (since 10/2015)
Prof. Dr. Ulf Ziemann Dr. Sarah Beyeler (until 12/2015)
Dr. Corinna Blum (since 12/2015)
Dr. Bettina Brendel
GROUP LEADERS/ATTENDING PHYSICIANS Dr. Christian Braun (until 05/2015)
Dr. Susanne Dietrich
Prof. Dr. Herrmann Ackermann Mahamed Yasser Elnaggar (since 03/2015)
PD Dr. Felix Bischof (until 07/2015) Dr. Kirsi Forsberg
PD Dr. Jennifer Diedler (Neurointensive Care, until 12/2015) Irina Gepfner-Tuma (since 01/2015)
Dr. Markus Krumbholz (since 07/2015) Dr. Parameswari Govindarajan
PD Dr. Christine Meyer-Zürn (Cardiologist) Florian Härtig
Dr. Florian Müller-Dahlhaus PD Dr. Ingo Hertrich
Prof. Dr. Ulrike Naumann Dr. Marilin Koch
Dr. Sven Poli, MSc (Stroke Unit) Luzie Köhler (since 06/2015)
Prof. Dr. Ghazaleh Tabatabai (Interdisciplinary Division Dr. Manfred Neumann (until 12/2015)
of Neuro-Oncology) Martin Ribitsch (since 04/2015)
Dr. Hardy Richter
Dr. Christina Roggia (since 07/2015)
Dr. Christoph Ruschil
Franscesca Russo (until 06/2015)
Dr. Susanne Schiemann (until 03/2015)
Dr. Dennis Schlak
Maria-Ioanna Stefanou
Johannes Tünnerhoff
Dr. Martin Wolf
Dr. Lena Zeltner
Dr. Carl Moritz Zipser
Dr. Christoph Zrenner
6
ANNUAL REPORT 2015
TECHNICAL STAFF/ADMINISTRATION PHD STUDENTS
Dipl.-Ing. Rüdiger Berndt (Electronics, Angela Armento (Supervisor Prof. Dr. Naumann)
together with the Dept. of Cognitive Neurology) Ghazal Darmani (since 02/2015) (Supervisor Prof. Dr. Ziemann)
Dilan Celik Debora Desideri (since 05/2015) (Supervisor Prof. Dr. Ziemann)
Evelyn Dubois Srinath Rajaraman (Supervisor Prof. Dr. Tabatabai)
Siegfried Ebner Sonja Schötterl (Supervisor Prof. Dr. Naumann)
Andrea Eckert Yi Wang (Supervisor Prof. Dr. Ulf Ziemann)
Sarah Hendel
Marion Jeric
Gabriele Kuebart (since 06/2015) MASTER STUDENTS
Ute Küstner (until 10/2015)
Fotini Scherer Rebecca Czolk (Supervisor Prof. Dr. Naumann)
Petra Schroth Maryam Geranmayeh (Supervisor PD Dr. Ingo Hertrich)
Julia Zeller Bingshuo Li (Supervisors Prof. Dr. Schwarz/ Prof. Dr. Ziemann)
Alisa Selent (Supervisor PD Dr. Ingo Hertrich)
Vivien Veninga (Supervisor Prof. Dr. Naumann)
MEDICAL DOCTORAL STUDENTS Ahmed Yousif (Supervisor Prof. Dr. Naumann)
Elina Brendle (Supervisor Prof. Dr. Tabatabai)
Heiko Brennenstuhl (Supervisor Prof. Dr. Naumann) LAB ROTATIONS
Elena Dangel (Supervisor Prof. Dr. Tabatabai)
Hulda Ewald (Supervisor Prof. Dr. Tabatabai) Florian Wedekink (Biochemie, Supervisor: Prof. Dr. Tabatabai)
Juliane Ebert (Supervisor Prof. Dr. Tabatabai) Vanessa Hertlein (Biochemie, Prof. Dr. Tabatabai)
Jakob Ehlers (Supervisor Prof. Dr. Naumann) Raika Sieger (Biochemie, Prof. Dr. Tabatabai)
Hanna Faber (Supervisor Prof. Dr. Ziemann)
Sandra Falkvoll (Supervisor PD Dr. Bischof)
Katharina Hadaschik (Supervisor Prof. Dr. Ziemann/Dr. Poli) PROFESSORSHIP FOR NEUROREHABILITATION
Ilona Hoberg (Supervisor PD Dr. Bischof)
Yeho-Irae Kim (Supervisor Prof. Dr. Ziemann) Prof. Dr. Herrmann Ackermann
Julia Elisabeth Király (Supervisor Prof. Dr. Ziemann) PD Dr. Ingo Hertrich
Franca Koenig (Supervisor Prof. Dr. Ziemann)
Natalya Korinetsko (Supervisor Prof. Dr. Tabatabai)
Xiaomin Li (since 10/2015) (Supervisor Prof. Dr. Ziemann)
Chen Liang (Supervisor Prof. Dr. Ziemann)
Anne Lieb (Supervisor Prof. Dr. Ziemann)
Philipp Nakov (Supervisor PD Dr. Bischof)
Katrin Schulz (Supervisor PD Dr. Bischof)
Claudius Speer (Supervisor PD Dr. Bischof)
Charlotte Spencer (Supervisor Prof. Dr. Ziemann/Dr. Poli)
Jakob Spogis (Supervisor Prof. Dr. Ziemann)
Natalia Tveriakhina (Supervisor PD Dr. Bischof)
Benjamin Walz (Supervisor PD Dr. Bischof)
Xueyu Yang (since 10/2015) (Supervisor Prof. Dr. Ulf Ziemann)
7
Department of Neurology and Stroke
Clinical Studies DEPTH-SOS: DEcompressive Surgery Plus Hypothermia
in Space Occupying Stroke.
Investigator: Sven Poli
STROKE STUDIES
Destiny-R: DEcompressive Surgery for the Treatment
ACTION (EudraCT: 2013‐001514‐15): A Multicenter, of malignant INfarction of the middle cerebral arterY –
Double-Blind, Placebo-Controlled, Randomized, Parallel- Registry.
Group Study to Evaluate the Safety and Efficacy of Investigator: Sven Poli
Intravenous Natalizumab (BG00002) on Reducing Infarct
Volume in Acute Ischemic Stroke ECASS-4 (EudraCT: 2012-003609-80): European Cooperative
Investigator: Sven Poli Acute Stroke Study-4. Extending the time for Thrombolysis
in Emergency Neurological Deficits, ECASS-4: ExTEND
ATACH-II: A Phase III Randomized Multicenter Clinical Trial Investigator: Sven Poli
of Blood Pressure Reduction for Hypertension in Acute
Intracerebral Hemorrhage EuroHYP1 (EudraCT: 2012-002944-25): EuroHYP-1:
Investigator: Sven Poli European multicentre, randomised, phase III clinical trial of
therapeutic hypothermia plus best medical treatment versus
ATTICUS: Apixaban for treatment of embolic stroke of best medical treatment alone for acute ischaemic stroke
undetermined source Investigator: Sven Poli
Investigator: Sven Poli
INCH (EudraCT-Nr.: 2008-005653-37): Multicenter,
CAPIAS: The carotid plaque imaging in acute stroke (CAPIAS) prospective randomized trial on the use of prothrombin
study: protocol and initial baseline data complex and fresh frozen plasma in patients with intra-
Investigator: Ulf Ziemann cerebral hemorrhage related to vitamin k antagonists.
Investigator: Sven Poli
CL1-44819-003: Effects of S 44819 on GABAergic system
measured by Transcranial Magnetic Stimulation (TMS) in MISTIE III: Minimally Invasive Surgery plus rt-PA for ICH
healthy young male volunteers. A phase I, monocentre, Evacuation Phase III
randomized, double-blind, placebo-controlled, cross-over Investigator: Sven Poli
study, with 3 treatment periods (placebo, S 44819 50 mg,
S 44819 100 mg. POCT-NOAC: Point-of-Care Messung der Blutgerinnung
Investigator: Prof. Dr. med. Ulf Ziemann bei Therapie mit neuen oralen Antikoagulantien.
Investigator: Sven Poli
CLEAR-IVH III (EudraCT-Nr.: 2008-00691-39): Clot Lysis:
Evaluating Accelerated Resolution of Intraventricular RASUNOA: Registry of acute stroke under new oral
Hemorrhage Phase III. anticoagulants (RASUNOA).
Investigator: Sven Poli Investigator: Sven Poli
CoolStroke1: COOLing for Normothermia in Stroke 1 RASUNOA-Prime: Register für Akute Schlaganfälle
(COOLStroke 1) – A Randomized, Controlled Trial to Unter Neuen Oralen Antikoagulantien – Prime
Evaluate the EMCOOLS Brain.Pad versus Cold Infusions for Investigator: Sven Poli
Normothermia Treatment in Awake Ischemic Stroke Patients
Investigator: Sven Poli RESPECT ESUS: Randomized, double-blind, Evaluation in
secondary Stroke Prevention comparing the Efficacy and
CoolStroke2: COOLing for Normothermia in Stroke 2 (COOL- safety of the oral Thrombin inhibitor dabigatran etexilate
Stroke 2) – A Randomized Pilot Trial Evaluating Intranasal (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid
Cooling with the QuickCool Device Adjunct to Standard (100 mg oral q.d.) in patients with Embolic Stroke of
Normothermia Treatment in Awake Ischemic Stroke Patients Undetermined Source
Investigator: Sven Poli Investigator: Sven Poli
8
ANNUAL REPORT 2015
REVACEPT (EudraCT-Nr.: 2011-001006-10): An inhibitor of CFTY720D2406 (PASSAGE): (NIS – Phase 4)
platelet adhesion in symptomatic carotid stenosis: A phase II, Prospektive, nicht-interventionelle, multinationale
multicenter, randomized, dose-finding, double-blind and Studie mit Parallel-Kohorten zur Bewertung der Langzeit-
placebo controlled superiority study with parallel groups. Sicherheit in Patienten mit MS, deren Behandlung kürzlich
Investigator: Sven Poli auf tägliche Fingolimod-Gabe umgestellt wurde oder die
mit einer anderen zugelassenen krankheitsmodifizierenden
Risikostratifizierung von Schlaganfallpatienten durch Therapie behandelt werden
Analyse der autonomen Funktion (AKF-Programm) Investigator: Felix Bischof/Markus Krumbholz
Investigators: Christine Meyer-Zürn, Jennifer Diedler
CFTY720DDE02 (PANGAEA-NIS – Phase 4): Multizentrische,
SITSopen: An open, prospective, international, multicentre, prospektive, nicht-interventionelle Langzeit-Registerstudie
controlled study of safety and efficacy of thrombectomy in zur Beschreibung der Sicherheit und des Stellenwerts von
acute occlusive stroke following initiation with intravenous Gilenya® (fingolimod 0.5 mg) in der Behandlung von MS
thrombolysis with alteplase in accordance with accepted Patienten.: Post-Authorization non-interventional German
guidelines, compared to intravenous thrombolysis only safety study of Gilenya® in MS patients.
Investigators: Sven Poli, Ulrike Ernemann Investigator: Felix Bischof/Markus Krumbholz
SPOCT-NOAC 1: Specific Point-of-Care Testing of CFTY720D2405 (TRANSITION): Eine zweijährige Beobach-
Coagulation in Patients Treated with Non-Vitamin K tungsstudie zur Untersuchung des Sicherheitsprofils von
Antagonist Oral Anticoagulants – Part Ia/b Fingolimod bei Patienten mit Multipler Sklerose, die von
Investigator: Sven Poli Natalizumab auf Fingolimod wechseln
Investigator: Felix Bischof/ Markus Krumbholz
WakeUP (EudraCT:2011-005906-32): Efficacy and safety of
MRI-based thrombolysis in wake-up stroke. a randomised, CFTY720DDE17 (START)(EudraCT-Nr. 2012-000653-32):
double-blind, placebo-controlled trial A 1-week, open-label, multicenter study to explore
Investigator: Sven Poli conduction abnormalities during first dose administration
of fingolimod in patients with relapsing-remitting multiple
sclerosis.
NEUROIMMUNOLOGY STUDIES Investigator: Felix Bischof/Markus Krumbholz
101MS326 (ASCEND): (EudraCT-Nr. :201-0-021978-11) A CFTY720D2399 (Longterms) (EudraCT-Nr. 2010-020515-37):
Multicenter, Randomized, Double-Blind, Placebo-Controlled A single arm, open-label, multicenter study evaluating
Study of the Efficacy of Natalizumab on Reducing Disability the long-term safety, tolerability and efficacy of a 0.5 mg
Progression in Subjects With Secondary Progressive fingolimod (FTY720) administered orally once daily in
Multiple Sclerosis. patients with multiple sclerosis.
Investigator: Felix Bischof/Markus Krumbholz Investigator: Ulf Ziemann
CD-IA-MEDI-551-1155 (Medi-551) (EudraCT Nr: 2014- Dimethyl fumarate: Influence of Dimethyl fumarate
000253-36): A Double-masked, Placebo-controlled Study (DMF) on fMRI markers of cortical resting state network
with Open-label Period to Evaluate the Efficacy and Safety connectivity in relapsing remitting multiple sclerosis
of MEDI-551 in Adult Subjects with Neuromyelitis Optica (RRMS).
and Neuromyelitis Optica Spectrum Disorder. Investigator: Ulf Ziemann
Investigator: Markus Krumbholz
Kompetenznetz MS: Concerted Action on Biomarker for
Individualized Multiple Sclerosis Therapy in Germany –
Control MS: Prospektive Kohortenstudie bei Patienten mit
KIS (klinisch isoliertem Syndrom) und früher Multipler
Sklerose.
Investigator: Ulf Ziemann
9Department of Neurology and Stroke
Clinical Studies GAPVAC-101: a phase I study using an innovative
individualized peptide vaccination-based immunotherapy
in newly diagnosed glioblastoma (www.gapvac.eu)
NEUROIMMUNOLOGY STUDIES Investigator: Ghazaleh Tabatabai, Sponsor: Immatics GmbH,
Tübingen
REGIMS Register:
Ein Immuntherapieregister zur Verbesserung der iMRI/5-ALA: a parallel group phase II trial to investigate
Arzneimittel-sicherheit in der MS-Therapie“ Investigator: maximum extent of resection based on iMRI versus 5-ALA.
Felix Bischof Investigator: Constantin Roder, Sponsor: University Hospital
Tübingen
TMP001_MS (TMP001) (EudraCT Nr: 2014-004483-38):
TMP001 in relapsing-remitting multiple sclerosis: a NOA12: Phase I/II trial exploring the combination of the
multicentre open, baseline-controlled phase IIa clinical trial. compound BIBF120 with re-irradiation versus re-irradiation
Investigator: Ulf Ziemann alone in progressive glioblastoma.
Investigator: Daniel Zips
WA 21493 OLE (EudraCT-Nr. 2007-006338-32): A Phase II,
multicenter, randomized, placebo and Avonex controlled
dose finding study to evaluate the efficacy and safety of
ocrelizumab in patients with relapsing-remitting multiple Third-Party Funding
sclerosis.
Investigator: Ulf Ziemann
ONGOING GRANTS
WA21092 (OPERA) (EudraCT-Nr. 2010-020337-99): A
Randomized, Double-Blind, Double-Dummy, Parallel-Group Terminal differenzierte B Lymphozyten bei Patienten
Study To Evaluate The Efficacy And Safety Of Ocrelizumab In mit Multipler Sklerose
Comparison To Interferon Beta-1a (Rebif®) In Patients With Project leader: PD Dr. Felix Bischof
Relapsing Multiple Sclerosis. Funding institution: Novartis
Investigator: Ulf Ziemann
Verarbeitung multimodaler emotionaler Signale
WA25046 (ORATORIO)(EudraCT-Nr.2010-020338-25): bei Patienten mit Multipler Sklerose
A Phase III, multicenter, randomized, parallel-group, Project leader: PD Dr. Felix Bischof
double-blinded, placebo-controlled study to evaluate the Funding institution: Novartis
efficacy and safety of ocrelizumab in adults with primary
progressive multiple sclerosis. Mechanismen des T Helfer Typ 9 induzierten neuronalen
Investigator: Ulf Ziemann Schadens
Project Leaders: PD Dr. Felix Bischof, Philipp Nakov
IZKF Promotionsstipendium
NEUROONCOLOGY STUDIES
Perception of speech at normal and ultra-fast syllable
CATNON Intergroup Trial (EORTC 26053): Phase III trial on rates - functional neuroplasticity in blind subjects and
concurrent and adjuvant temozolomide chemotherapy in its relation to the normal speech processing network
non-1p/19q deleted anaplastic glioma. (DFG HE 1573/6-2)
Investigator: Ghazaleh Tabatabai, Sponsor: EORTC Project Leader: PD Dr. Ingo Hertrich
Funding institution: Deutsche Forschungsgemeinschaft (DFG)
EORTC 26101: Phase II trial exploring the sequence
of bevacizumab and lomustine in patients with first
recurrence of glioblastoma (will be expanded from 2014
as Phase III trial).
Investigator: Ghazaleh Tabatabai, Sponsor: EORTC
10ANNUAL REPORT 2015
Cardiac Autonomic Function for Risk Prediction in Nichtinvasive zentrale Schmerzmodulation durch TMS-
Cryptogenic Stroke (CRYPTIC-Study) Hemmung des sekundären somatosensorischen Kortex
Project leader: PD Dr. Christine Meyer-Zürn, Dr. Sven Poli, gesunder Probanden
PD Dr. Jennifer Diedler Project leader: Prof. Dr. Jörn Lötsch, Prof. Dr. Ulf Ziemann
Funding institution: Medtronic Funding institution: Deutsche Forschungsgemeinschaft (DFG)
Erforschung der molekularen Mechanismen einer ISCADOR Bewegungsverklanglichung zur Rehabilitation der
Behandlung des Glioblastoms Armmotorik nach Schlaganfällen
Project leader: Prof. Dr. Ulrike Naumann Project Leader: Prof. Dr. Eckart Altenmüller (Hochschule für
Funding institution: Innovationsstiftung Ulrike Sauer, Musik, Theater und Medien Hannover), Prof. Dr. Udo Dahmen
Förderverein komplementärmedizinische Forschung (Popakademie Baden-Württemberg), Prof. Dr. Ulf Ziemann
Funding institution: Hertie Foundation
Funktionelle und therapeutische Bedeutung
des Neuropeptid-prozessierenden Enzyms Strengthening the SMA-M1 connection of human motor
Carboxypeptidase E im Glioblastom cortex by a novel non-invasive brain
Project leader: Prof. Dr. Ulrike Naumann stimulation protocol to enhance motor performance
Funding institution: German Cancer Foundation and learning (DFG ZI 542/7-1)
Project Leader: Prof. Dr. Ulf Ziemann
Funktionelle und therapeutische Bedeutung einer Funding institution: Deutsche Forschungsgemeinschaft (DFG)
Behandlung des Glioblastoms mit Mistellektinen
Project leader: Prof. Dr. Ulrike Naumann Drug Repositioning for Multiple Sclerosis - DrugRep-
Funding institution: Software AG Teilvorhaben Zentrale Studienleitung (BMBF 16GW0059)
Project Leader: Prof. Dr. Ulf Ziemann
Funktionelle Bedeutung der in Perizyten Gliom-assoziierter Funding institution: Bundesministerium für Bildung
Gefäße exprimierten EMT-Faktoren SLUG, SNAIL und TWIST und Forschung (BMBF)
Project Leader: Prof. Dr. Ulrike Naumann
Funding institution: Henriette und Otmar Eier-Stiftung, Influence of Dimethylfumarate (DMF) on fMRI markers
IZKF Promotionskolleg of cortical resting state network connectivity in relapsing
remitting multiple sclerosis (RRMS)
COOLing for Normothermia in Stroke 1 (COOLStroke 1) Project Leader: Prof. Dr. Ulf Ziemann
Project Leader: Dr. Sven Poli Funding institution: Biogen Idec GmbH
Funding institution: EMCOOLS Medical Cooling Systems AG,
Brucknerstr. 6-7a, 1040 Wien, Austria Inhibition in the somatosensory system: an integrated
neuropharmacological and neuroimaging approach
Berufung von Spitzenmedizinern aus dem Ausland Project Leaders: Prof. Dr. Ulf Ziemann / Prof. Dr. Christoph Braun
Project Leader: Prof. Dr. Ghazaleh Tabatabai Funding institution: Werner Reichardt Centre for Integrative
Funding institution: Else Kröner Fresenius Stiftung / Neuroscience (CIN)
German Scholars Organization
Induction of brain plasticity with closed-loop EEG-triggered
Pharmacological characterization of TMS-EEG biomarkers transcranial magnetic stimulation
of excitability and effective connectivity in human cortex Project Leaders: Dr. Christoph Zrenner
Project leader: Prof. Dr. Ulf Ziemann Funding institution: Medical Faculty University Tübingen,
Funding institution: Werner Reichardt Centre for Integrative Fortüne Program
Neuroscience (CIN)
Correlated oscillations as biomarkers of neuronal
dysfunction in multiple sclerosis
Project leader: Prof. Dr. Ulf Ziemann, Prof. Dr. Markus Siegel
Funding institution: Werner Reichardt Centre for Integrative
Neuroscience (CIN)
11Department of Neurology and Stroke
Third-Party Funding Effects of S 44819 on GABAergic system measured by
Transcranial Magnetic Stimulation (TMS) in healthy young
male volunteers
NEW GRANTS Leader: Prof. Ulf Ziemann
Funding institution: Institut de Recherches Internationales
Influence of tumor irradiation on glioma therapy Servier (I.R.I.S.)
using the oncolytic adenovirus Ad-Delo3-RGD
Project Leader: Prof. Dr. Ulrike Naumann Inhibition in the somatosensory system: an integrated
Funding institution: Else-Übelmesser-Stiftung neuropharmacological and neuroimaging approach
Project Leaders: Prof. Dr. Ulf Ziemann,
COOLing for Normothermia in Stroke 2 (COOLStroke 2) Prof. Dr. Christoph Braun
Project Leader: Dr. Sven Poli Funding institution: Werner Reichardt Centre
Funding institution: QuickCool AB, Lund, Sweden for Integrative Neuroscience (CIN)
Interdisciplinary translational Neuro-Oncology from Induction of brain plasticity with closed-loop EEG-triggered
molecular alterations to patient stratification and therapy transcranial magnetic stimulation
Project Leader: Prof. Tabatabai Project Leaders: Dr. Christoph Zrenner
Funding institution: Medical Faculty Tübingen Funding institution: Medical Faculty University Tübingen,
Fortüne Programme
Individualizing the treatment of CNS Metastases
Project Leader: Prof. Tabatabai
Funding institution: Medical Faculty Tübingen
Awards
Apixaban for treatment of embolic stroke of undetermined
source (ATTICUS randomized trial) Ulf Ziemann
Leaders: Prof. Tobias Geisler / Prof. Ulf Ziemann Listing “Top Physicians 2015” (Guter Rat)
Funding institution: Bristol-Myers Squibbs
An exploratory study assessing TMS plasticity deficits
in patients with AD and aMCI in comparison to healthy Medical Theses
controls (Completed in 2015)
Leaders: Prof. Ulf Ziemann / Prof. Daniela Berg /
Prof. Christoph Laske Toni Silber
Funding institution: Janssen Pharmaceuticals NV Periinterventionelle Komplikationen der perkutanen
Angioplastie und Stentimplantation in Stenosen
Implantable, bidirectional Brain-Computer-Interface intrakranieller Arterien in 46 Patienten
for restoration of motor functions (MOTOR-BIC) Supervisor: PD Dr. Felix Bischof
Leaders for Tübingen Project: Prof. Niels Birbaumer /
Prof. Ulf Ziemann Johannes Mörike
Funding institution: BMBF Die Bedeutung der N-Glykosylierung von T-Zell
Populationen in der Experimentellen Autoimmunen
Study center for neuro-cardio-vascular emergency Enzephalomyelitis
and intensive care medicine (NKVNI) Supervisor: PD Dr. Felix Bischof
Leaders: Profs. Gawaz / Schlensak / Tatagiba / Ziemann
Funding institution: Medical Faculty Tübingen Jan Piel
Der Einfluss von immunmodulierender Therapie
auf die Glykosylierung von Immunzellen bei Patienten
mit schubförmiger multipler Sklerose
Supervisor: PD Dr. Felix Bischof
12ANNUAL REPORT 2015
Bachelor Theses
(Completed in 2015)
Roland Genthner
Gesten – Neurales Spektrum und Bedeutung
für die Sprachverarbeitung
Supervisor: PD Dr. Ingo Hertrich
Sarah Hafner
Individuelle Unterschiede beim Lippenlesen –
In Zusammenhang mit dem McGurk Effekt
Supervisor: PD Dr. Ingo Hertrich
Ricarda Farsch
Hintergründe der filler „äh, ähm“, ihre Wirkung
auf den Hörer und die Kommunikation
Supervisor: PD Dr. Ingo Hertrich
Diploma/Master Theses
(Completed in 2015)
Simone Burkhardt
The relevance of interleukin 6 and CXCL10 in Th9 cell
mediated neuronal damage
Supervisor: PD Dr. Felix Bischof.
Guest Researcher
Prof. Dr. Luis Velazquez-Perez, Cuba (Awardee of a Georg
Forster Research Award of the Alexander-von-Humboldt
Foundation)
Host: Prof. Dr. Ziemann
Dr. Nigel Rogasch, Monash University, Melbourne, Australia
(Awardee of DAAD short term grant)
Host: Prof. Dr. Ziemann
13Department
of Neurology
and
Epileptology
Clinical and Scientific Staff SCIENTISTS/RESIDENTS
Eva Auffenberg
HEAD OF THE DEPARTMENT Felicitas Becker
Merle Bock
Prof. Dr. Holger Lerche Dr. Nele Dammeier
Dr. Gina Elsen (until 07/2015)
Adham Elshahabi
GROUP LEADERS/ATTENDING PHYSICIANS Dr. Caroline Freilinger
Samira Hamzehian (since 08/2015)
PD Dr. Niels Focke Dr. Ulrike Hedrich
PD Dr. Tobias Freilinger Haosi Huang (since 08/2015)
Dr. Alexander Grimm (since 05/2015) Ashish Kaul Sahib
Prof. Dr. Yvonne Weber Josua Kegele
Dr. Snezana Maljevic Dr. Silke Klamer
Prof. Dr. Marcel Dihné Dr. Henner Koch
Stefan Lauxmann
Christina Lipski
Dr. Yuanyuan Liu
Dr. Pascal Martin
Justus Marquetand
Stephan Müller (until 07/2015)
Cristina Niturad
Harshad PA (since 09/015)
Dr. Filip Rosa
Dr. Julian Schubert
Dr. Victoria Schubert
Dr. Niklas Schwarz (since 01/2015)
Dr. Sören Stirn (until 04/2015)
Debora Vittore (since 03/2015)
Dr. Nathalie Winter
Dr. Stefan Wolking
Dr. Thomas Wuttke
Pu Yan (since 09/2015)
14ANNUAL REPORT 2015
TECHNICAL STAFF/ INTERNSHIPS
ADMINISTRATION
Sara Bertelli
Dr. Patricia Beck Supervisors: PD Dr. Tobias Freilinger, Dr. Ulrike Hedrich
Ana Fulgencio-Maisch
Christian Hengsbach Natalie Agarwala
Heidrun Löffler Supervisor: Dr. Ulrike Hedrich
Katja Michaelis
Sarah Rau Sabina Vejzovic
Susanne Stimmler Supervisor: Dr. Snezana Maljevic
Doris Wieder
Nicole Zepezauer (bis 12/2015) Norman Sinnigen
Supervisor: Dr. Ulrike Hedrich
MEDICAL DOCTORAL Chieh-Yu Cheng
STUDENTS Supervisor: Dr. Yuanyuan Liu
Philipp-Justus Lührs Sinthyia Ahmed
Niklas Vogel Supervisor: Dr. Julian Schubert
Katharina Hof
Julia Knaus Carolin Schilpp
Nicole Kusch Supervisor: Dr. Ulrike Hedrich
Andreas Naros
Siona Pfeffer Felicitas Horn
Theresa Simperl Supervisors: Dr. Snezana Maljevic, Stephan Müller
Anna Wagner
Andreas Naros Lena Rüschtroer
Niklas Schwarz Supervisor: Dr. Ulrike Hedrich, Dr. Julian Schubert
Janine Brandes
Supervisor: Dr. Henner Koch
Lisa Kirchberger
Supervisor: Dr. Yuanyuan Liu, Dr. Snezana Maljevic
15Department of Neurology and Epileptology
Clinical Studies PredCh – Efficacy and safety of oral prednisone as add-on
therapy in prophylactic treatment of episodic cluster
headache: a randomized, placebo controlled parallel study
CLINICAL STUDIES Investigator: PD Dr. Tobias Freilinger
ZEDEBAC: A multicenter, open-label and non-interventional A randomized, controlled, double-blind, two-arm clinical
study to investigate Eslicarbazepinacetat in focal epilepsies. trial to assess safety and efficacy of transcutaneous vagus
Investigator: Prof. Dr. Yvonne Weber nerve stimulation (t-VNS®) in patients with drug-resistant
epilepsy.
Artemis: A Randomized, Double-Blind, Placebo Controlled Investigator: Prof. Dr. Yvonne Weber
Trial Examining the Safety and Efficacy of Midazolam
Intranasal Spray (USL261) for the Treatment of Intermittent Vibes: A noninterventional study of Vimpat (lacosamide)
Bouts of Increased Seizure Activity in the Epilepsy added to one baseline antiepileptic drug therapy in
Monitoring Unit patients with brain tumor-related epilepsy.
Investigator: Prof. Dr. Yvonne Weber Investigator: Prof. Dr. Yvonne Weber
SP0982: A double-blind, randomized, placebo-controlled, A multicenter, single-arm, open-label, post-marketing
parallel-group, multicenter study to evaluate the efficacy safety study to evaluate the risk of seizure among subjects
and safety of lacosamide as adunctive therapy for uncon- with metastatic castration-resistant prostate cancer treated
trolled primary generalized tonic-clonic seizures in subjects with enzalutamide who are at potential increased risk of
with IGE seizure.
Investigator: Prof. Dr. Yvonne Weber Investigator: Prof. Dr. Yvonne Weber
EP0077: A 12-month noninterventional, postmarketing A randomized, placebo-controlled, double-blind, multi‐
multicentre study fo evaluate the effectiveness of briva- center clinical investigation to evaluate the performance
racetam as adjunctive therapy in patients with epilpesy and safety of the chordate system when used in the treat‐
with partial-onset ment of acute migraine attacks of moderate to
Investigator: Prof. Dr. Yvonne Weber severe intensity.
Investigator: PD Dr. Tobias Freilinger
Vibes: A noninterventional study of Vimpat (lacosamide)
added to one baseline antiepileptic drug therapy in patients PredCh – Efficacy and safety of oral prednisone as add-on
with brain tumor-related epilepsy. therapy in prophylactic treatment of episodic cluster head‐
Investigator: Prof. Dr. Yvonne Weber ache: a randomized, placebo controlled parallel study
Investigator: PD Dr. Tobias Freilinger
A multicenter, single-arm, open-label, post-marketing
safety study to evaluate the risk of seizure among subjects
with metastatic castration-resistant prostate cancer
treated with enzalutamide who are at potential increased Third-Party Funding
risk of seizure.
Investigator: Prof. Dr. Yvonne Weber
GRANTS
A randomized, placebo-controlled, double-blind, multi‐
center clinical investigation to evaluate the performance Recruitment of patients with epilepsy for genetic
and safety of the chordate system when used in the and pharmacogenetic examinations
treatment of acute migraine attacks of moderate to [Rekrutierung von Patienten für genetische und
severe intensity. pharmakogenetische Untersuchungen bei Epilepsien]
Investigator: PD Dr. Tobias Freilinger Project leader: Prof. Dr. Holger Lerche, Prof Dr. Yvonne Weber
Funding Institution: German Society for Epileptology,
UCB Pharma, foundation ‘no epilep’
16ANNUAL REPORT 2015
Epilepsy Pharmacogenomics: Delivering biomarkers Pathomechanisms of aquired epilepsy autoimmune
for clinical use (EpiPGX) until 10/2015 disorders associated with anti-NMDA receptor and anti-LG1
Project leader: Prof. Dr. Holger Lerche (Deputy coordinator) autoantibodies
Funding institution: EU Seventh Framework Programme Project leader: Dr. Gina Elsen
(FP7) (EU-279062) Funding institution: University of Tübingen (fortüne)
German Network of Neurological and Ophthalmological Tri-Modal Network-Analysis using [18F]FDG-PET, fMRI
Ion Channel Disorders (IonNeurONet) until 08/2015 and HD-EEG
Project leader: Prof. Dr. Holger Lerche (Network-Coordinator), Project leader: PD Dr. Niels Focke
Dr. Snezana Maljevic (Project leader) Funding institution: University of Tübingen (CIN pool
Funding institution: Federal Ministry of Education project)
and Research (BMBF Network Rare Diseases)
Gene panel diagnostic testing for patients with epilepsy NEW GRANTS
[Gen-Panel Diagnostik bei Patienten mit Epilepsie]
Project leader: Prof. Dr. Yvonne Weber Exploring the function of the central control of breathing
Funding institution: University of Tübingen (AKF) in mice with sodium-channel mutationscausing epilepsy,
implications for sudden unexpected death in patients
Evaluating voxel-based functional connectivity with epilepsy (SUDEP)
measures in epilepsy [Die zentrale Kontrolle der Atmung in Mäusen mit
Project leader: PD Dr. Niels Focke Natriumkanalmutationen, die Epilepsien verursachen
Funding institution: University of Tübingen (CIN pool project) und die Implikation für den plötzlichen unerwarteten Tod
bei Epilepsie]
Pathophysiology of the familial hemiplegic migraine: Project leader: Dr. Henner Koch
Examination of a newly developed transgenic SNC1A Funding institution: German Research Foundation (DFG)
mouse model (KO 4877/2-1)
[Pathophysiologie der familiären hemiplegischen Migräne:
Untersuchung an einem neu entwickelten transgenen Post processing in epileptology
SCN1A Mausmodell] Project leader: PD Dr. Niels Focke
Projet leader: PD Dr. Tobias Freilinger Funding institution: University of Tübingen (AKF)
Funding institution: German Research Foundation (DFG)
(FR 3324/2-1) In vivo approaches to study seizure generation and cortical
spreading depression in two- and three-dimensions
Pathophysiology of non-classical epileptic in awake Scn1a knock-in mouse models for idiopathic
encephalopathies (EE) epilepsy and migraine.
[Pathophysiologie von nicht klassischen epileptischen Project leader: Dr. Ulrike Hedrich
Enzephalopathien (EE)] Funding institution: University of Tübingen (fortüne)
Project leader: Prof. Dr. Yvonne Weber
Funding institution: German Research Foundation (DFG) Exist Gründerstipendium Epilog. Etablierung eines Devices
(WE 4896/3-1) zur Anfallsdeduktion (Bundesministerium für Wirtschaft
und Energie (O3EGSBW299))
Prophlyactic treatment of hemiplegic migraine
with lamotrigine – a pilot study
Project leader: PD Dr. Tobias Freilinger
Funding institution: Centre for Rare Diseases, Tübingen
17Department of Neurology and Epileptology
Diploma/Master/Doctoral Guest Researchers
Theses Sandra Kruszynski (PATE)
Host: Dr. Henner Koch
BACHELOR
Kevin Klett
Norman Sinnigen Hosts: Prof. Dr. Y. Weber, Dr. Henner Koch
Effect of 4-Aminopyridin on the de novo Kv1.2 mutations
R297Q und L298F by using two-electrode voltage clamp Florian Lutz
recordings in Xenopus laevis oocytes Hosts: Prof. Dr. Y. Weber, Dr. Henner Koch
Supervisor: Dr. Ulrike Hedrich
MASTER
Sabina Vejzovic
Functional expression of epilepsy-related mutations
in KCNQ2 and KCNQ3 genes
Supervisor: Dr. Snezana Maljevic
MD THESES
Andreas Naros
Neuronale Expressionsmuster von ClC2 Cl- Kanälen
Supervisors: Dr. Snezana Maljevic, Prof. Dr. Holger Lerche
Julia Knaus
Funktionelle Analyse von GABRA5 Mutationen
bei idiopathischer generalisierter Epilepsie
Supervisors: Dr. Snezana Maljevic, Prof. Dr. Holger Lerche
18ANNUAL REPORT 2015
19Department of Neurodegenerative Diseases
Department
of Neuro-
degenerative
Diseases
Clinical and Scientific Staff SCIENTISTS/RESIDENTS/PHD STUDENTS
Dr. Anja Apel
HEAD OF THE DEPARTMENT Burcu Atasu
Felix Bernhard
Prof. Dr. Thomas Gasser Dominik Blum
Dr. Kathrin Brockmann
Christine Bus
DEPUTY HEAD OF THE DEPARTMENT Andres Caballero
Silvia De Cicco
Prof. Dr. Ludger Schöls Morad Elshehabi
Dr. Julia Fitzgerald
Dr. Natalja Funk
GROUP LEADERS/ATTENDING PHYSICIANS Dr. Sven Geisler
Anamika Giri
Prof. Dr. Daniela Berg Dr. Susanne Gräber-Sultan
Dr. Dr. Saskia Biskup Dr. Idil Hanci
Dr. Dr. Michela Deleidi Dr. Friederike Hans
Prof. Dr. Philipp Kahle Dr. Stefan Hauser
Prof. Dr. Rejko Krüger (Group leader at large since 06/2014) Dr. Stefanie Hayer
Prof. Dr. Walter Maetzler Dr. Holger Hengel
Dr. Rebecca Schüle Dr. Sebastian Heinzel
Dr. Javier Simón-Sánchez ( jointly with DZNE-Tübingen) Markus Hobert
Dr. Matthis Synofzik Philip Höflinger
Dr. Sandra Jäckel
Dr. Jennifer Just
Stefanie Krüger
Dr. Martin Kuss
Dr. Stefanie Lerche
Dr. Inga Liepelt-Scarfone ( jointly with DZNE)
Dr. Ebba Lohmann
Minh Hoang Pham
Dr. Andrea Pilotto
Dr. Tim Rattay
Erik Riesch
20ANNUAL REPORT 2015
Dr. Benjamin Roeben Lukas Kristoffer Schwarz Annegret Leuser
Dr. Lorenzo Roncoroni Susanne Stimmler Mirjam Mächtel
Dr. Carola Rotermund Dr. Anna-Katharina v. Thaler Katrin Maier
Dina Salkovic Yvonne Theurer Julian Meinhardt
Dr. Eva Schäffer Doris Wieder Maxim Nechyporenko
David Schöndorf Maria Zarani Theofanis Ngamsri
Marlieke Scholten Senait Ogbamicael
Claudia Schulte Franziska Ott
Katharina Stegen MEDICAL DOCTORAL Sylvia Pflederer
Ulrike Sünkel STUDENTS Natalie Philipp
Marion Thierfelder (until 09/2015) Kathrin Prahl
Catherine Thömmes Grammato Amexi Sarah Renno
Zuzanna Tkaczynska Carolin Bellut Ellen Riedel
Janet van Uem Alice Bernard Pavel Saraykin
Ulrike Ulmer Kristina Bettecken Jennifer Sartor
Dr. Adam Vogel Aline Beyle Saskia Schattauer
Dr. Gudrun Walter Stefanie Brand Carina Schelling
Dr. Daniel Weiß Jan-Hinrich Busch Alina Schermann
Dr. Carlo Wilke Gabriela Carvajal Anna Schöllmann
Dr. Richard Wüst Bernhard Cerff Patricia Schöpfer
Isabel Wurster Meltem Ciliz David Scheibner
Dr. Rezzak Yilmaz Sarah Dilger Norbert Silimon
Daniela Egic Johannes Sprengel
Karl Friedrich Ermisch Jana Stäbler
TECHNICAL STAFF/ Ellen Fehlert Lena Stetz
ADMINISTRATION Zofia Fleszar Stefan Streich
Amina Flinsbach Eva-Maria Strohmeier
Maren Albers Jasmin Fritzen Margarete Teresa Walach
Cindy Boden Florian Funer Melanie Wayand
Christian Deuschle Judith Greiner David Weiss
Christian Erhardt Katharina Greulich Simon Weiss
Dr. Jutta Eymann Eva Grüner Sofie Weiss
Dr. Bettina Faust Leonie Guggolz Laura Zaunbrecher
Katharina Gauss Alexandra Gutfreund Florian Zirbs
Christine Haaga Elena Hager
Ann-Kathrin Hauser Jochen Hallwachs
Tanja Heger Linda Härtner MASTER STUDENTS
Heiderose Heiss Melanie Heilbronn
Susanna Hoffmann Madeleine Heim Melanie Erzler
Maike Hoffmeister Philipp Hemmann Madeline Jäggle
Dina Ivanjuk Hanna Hentrich Friederike Klumpp
Sandra Kauenhowen Sonja Herrmann Beatriz Molina Martínez
Mirjam Knöll Max Hollweck Selina Reich
Jürgen Kronmüller Svenja Hucker Ulrike Ulmer
Manuela Kübler Daniel Holz
Isolde Marterer Malte Kampmeyer
Corina Maetzler Irenee Kanyiki DIPLOMA STUDENTS
Petra Mech Christoph Kessler
Katja Michaelis Johannes Klemt Sonja Golombek
Marita Munz Rosa Klotz Philip Höflinger
Susanne Nussbaum Anika Koch Max Güldner
Dr. Angelika Oehmig Sebastian Kormeier Christiane Halder
Ina Posner Lena Kuhn Rahel Lewin
Jennifer Reichbauer Ebru Kusku
Nicole Runge Sandra Lachenmaier
21Department of Neurodegenerative Diseases
Clinical Studies MODEP (Modeling Epidemiological Data to study
Parkinson’s disease progression): Monocenter longitudinal
observational study in Parkinson’s disease
Promesa: Double blind, randomised, prospective placebo Investigators: group of Prof. Dr. Walter Maetzler and
controlled parallel group phase III study to investigate the Prof. Dr. Daniela Berg
effect of EGCG supplementation on disease progression of
patients with multiple system atrophy. PPMI – The Parkinson’s Progression Markers Initiative
Investigators: Dr. Eva Schäffer, Prof. Dr. Daniela Berg (please see: http://www.ppmi-info.org/)
mutlicenter longitudinaI observational study in PD
Kyowa 6002-14: A 12-week, double-blind, placebo- Investigators: group of Prof. Dr. Daniela Berg
controlled, randomized, multicenter, phase III study to
evaluate the efficacy of oral Istradefylline 20 and 40 mg/ P-PPMI (please, see also: Fox-Trial-Finder): Prodromal
day as a treatment for patients with moderate to severe Parkinson’s Progression Markers Initiative: Mutlicenter
Parkinson’s disease. longitudinaI observational study in individuals at risk for PD
Investigators: Dr. Eva Schäffer, Prof. Dr. Daniela Berg Investigators: group of Prof. Dr. Daniela Berg
NIS-Azilect: In Azilect® Wearing -Off ( aiwo ) – Evaluation of ABC-PD: monocenter longitudinal study on the predictive
symptomatic efficacy and tolerability of rasagiline (Azilect®) value of CSF abeta-pathology for PD dementia.
in PD patients with wearing-off / end-of-dose akinesia, Investigators: Dr. Inga Liepelt and group of
using the wearing- off Questionnaires -32 ( WOQ -32) in Prof. Dr. Daniela Berg
daily practice.
Investigators: Dr. Eva Schäffer, Prof. Dr. Daniela Berg DEMPARK / LANDSCAPE: mutlicenter longitudinal
observational study on dementia in Parkinson’s disease.
PD0013-Neupart: A multicenter non-interventional Investigators: Dr. Inga Liepelt and group of
study to evaluate the effectiveness of Neupro® (rotigotin Prof. Dr. Daniela Berg
transdermal patch) and levodopa combination therapy in
patients with Parkinson’s disease. TREND-Studie (Tübinger evaluation of Risk factors for Early
Investigators: Dr. Eva Schäffer, Prof. Dr. Daniela Berg detection of NeuroDegeneration): Monocenter longitudi‐
nal observational study on individuals at high risk for PD
NIC-PD: A randomized, placebo-controlled, double-blind, to determine the value of risk, prodromal and progression
multicenter study to evaluate a possible disease-modifying markers in the prodromal phase.
effect of transdermal nicotine applique (nicotine patches) Please, see also: http://www.trend-studie.de/english/
in early stages of Parkinson’s disease. Investigators: group of Prof. Dr. Walter Maetzler and
Investigators: Dr. Isabel Wurster, Prof. Dr. Daniela Berg Prof. Dr. Daniela Berg
Ergotherapie bei Essentiellem Tremor (ET): A monocenter iMed-Studies: Within this German-wide project, Tübingen
single blind study to evaluate the symptomatic effect of is involved in several studies to understand the relation of
ergotherpy on ET Parkinson‘s disease and diabetes.
Investigators: Dr. Isabel Wurster, Prof. Dr. Daniela Berg These include:
1) Serologic infectious markers and oral microbiom
Ergotherapie bei Parkinson (PD): A monocenter single blind in relation to neuro-degenerative diseases and HbA1c
study to evaluate the symptomatic effect of ergotherpy on PD values
Investigators: Dr. Eva Schäffer, Prof. Dr. Daniela Berg 2) Evaluation of the influence of diabetes and prediabetes
on cognitive markers
Training PD: A monocenter center study assessing the 3) Genomic stratification of a subgroup of PD patients
clinical and neuroimaging effect of various trainings with diabetes
(physiotherapy, brain games, exergaming) in PD. 4) Evaluation of hypoglycemia and cognitive decline
Investigators: Dr. Eva Schäffer, Dr. Benjamin Roeben, in a cohort of diabetes patients
Prof. Dr. Daniela Berg 5) Association of plasma Aβ40 peptides with coronary
artery disease and diabetes mellitus
22ANNUAL REPORT 2015
6) Targeted proteomics for prediction of diabetes Multicenter evaluation of the effect of botulinum toxin
and neurodegeneration therapy on quality of life: A multicenter, non-interventional,
7) Changes in carbohydrate intake in PD prospective study to investigate the effect of botulinum
8) Metabolomics in PD-Patients with Diabetes. A toxin therapy on quality of life in previously not treated
cooperation with CETICS Health Solutions GmbH patients with various neurological diseases.
Investigators: Dr. Eva Schäffer, Dr. Benjamin Roeben, Investigators: Dr. Katerina Freitag, Prof. Dr. Thomas Gasser
Prof. Dr. Daniela Berg
EarlyStim – Post study follow up: The effect of deep brain
MIGAP: (Markers in GBA-associated PD) multicenter study stimulation of the subthalamic nucleus (STN-DBS) on
of the DZNE to detect biomarkers and protective factors in quality of life in comparison to best medical treatment
GBA-associated PD. in patients with complicated Parkinson’s disease and
Investigators: Dr. Kathrin Brockmann, Claudia Schulte, preserved psychosocial competence.
Prof. Dr. Daniela Berg Investigators: Prof. Dr. Rejko Krüger, Dr. Daniel Weiss
A phase III, randomised, double-blind and open label phase, StimCP – Effect of deep brain stimulation in the globus
active and placebo controlled study comparing the short pallidus internus on the quality of life of young patients
term efficacy of two formulations of clostridium botulinum with dyskinetic cerebral palsy (CP)
type A toxin (Dysport and Dysport RU) to placebo, and Investigators: Prof. Dr. Rejko Krüger, Dr. Daniel Weiss
assessing the short and long term efficacy and safety of
Dysport RU following repeated treatments of subjects with Health-related quality of life in LCIG-treated and LCIG-
cervical dystonia (CD). (IPSEN N°Y-52-52120-134.) amenable Patients with continued oral dopaminergic
Investigators: Dr. Tobias Wächter, Dr. Kathrin Brockmann, therapy. Non-interventional, multicentre observational trial
Prof. Dr. Thomas Gasser for levodopa-carbidopa gel (LCIG) in Germany – BALANCE
Investigators: Dr. Daniel Weiss
A94-52120-165: A national, multicenter, non-interventional,
prospective, longitudinal study of treatment with Functional electrical stimulation in hereditary spastic
botulinum toxin A injections in previously treated or paraplegia
untreated patients with cervical dystonia (Dysport®). Investigators: Dr. Rebecca Schüle, Dr. Tim Rattay,
Investigators: Dr. Tobias Wächter, Dr. Katerina Freitag, Prof. Dr. Ludger Schöls
Prof. Dr. Thomas Gasser
Statin Treatment of Oxysterol Pathology in SPG5
A 94-52120-174: An international, multicenter, non- (STOP SPG5)
interventional, prospective, longitudinal study to investigate Investigators: Dr. Rebecca Schüle, Dr. Tim Rattay,
the effectiveness of botulinum toxin A (Dysport®) injections Prof. Dr. Ludger Schöls
in patients suffering from post-stroke arm spasticity with
respect to early, medium or late start of treatment. Physiotherapie bei Hereditärer Spastischer Spinalparalyse
Investigators: Dr. Katerina Freitag, Prof. Dr. Thomas Gasser (HSP)
Investigators: Dr. Rebecca Schüle, Dr. Tim Rattay,
AGN191622: BOTOX prophylaxis in chronic migraine. Prof. Dr. Ludger Schöls
An international, multicentre, non-interventional,
prospective study of treatment with botulinum toxin Natural history in Hereditary Spastic Paraplegia (HSP
A injections in patients with chronic migraine. registry)
Investigators: Dr. Katerina Freitag, Prof. Dr. Thomas Gasser Investigators: Dr. Rebecca Schüle, Dr. Sarah Wiethoff,
Prof. Dr. Ludger Schöls
Y-79-52120-166: An international observational prospective
study on long-term response to botulinum toxin type a European Friedreich’s Ataxia Consortium for Translational
(BoNT-A) injections in subjects suffering from idiopathic Studies (EFACTS)
cervical dystonia (CD) – pharmaco-economic impact Investigators: Prof. Dr. Ludger Schöls, Dr. Jennifer Just,
(INTEREST IN CD2). Prof. Dr. Jörg Schulz (Aachen)
Investigators: Dr. Katerina Freitag, Prof. Dr. Thomas Gasser
23Department of Neurodegenerative Diseases
Sporadic ataxia with adult onset: Natural history Third-Party Funding
study (SPORTAX)
Investigators: Prof. Dr. Ludger Schöls, Dr. Matthis Synofzik,
Prof. Dr. Thomas Klockgether (Bonn) ONGOING GRANTS
Early onset ataxia: Genetic basis and natural history (EOA) Landscape
Investigators:Dr. Matthis Synofzik, Prof. Dr. Ludger Schöls Project leader: Prof. Dr. Daniela Berg
Funding institution: Federal Ministry of Education
MOVE’ n UP: Video game-based coordinative training and Research (BMBF)
for children with advanced degenerative ataxia
Investigators: Dr. Matthis Synofzik, Dr. Winfried Ilg JPND working group “Standardization of biomarker studies
in longitudinal studies of Parkinson’s disease”
Detecting PreAtaxia: A mixed challenge strategy Project leader: Prof. Dr. Daniela Berg
to identify ataxia at its preclinical stage Funding institution: Federal Ministry of Education
Investigators: Dr. Matthis Synofzik, Dr. Winfried Ilg and Research (BMBF)
A randomised delayed entry trial of intensive home-based Joint Research Project “Identification of prediction and
speech therapy in spinocerebellar ataxias progression biomarkers in the earliest stages of Parkinson’s
Investigators: Dr. Matthis Synofzik, Dr. Adam Vogel Disease (Neuro-D13B)”
(Univerity of Melbourne) Project leader: Prof. Dr. Daniela Berg, Prof. Dr. Walter Mätzler,
Prof. Dr. Olaf Riess (UKT)
A randomised delayed entry trial of intensive home-based Funding institution: Federal Ministry of Education and
speech therapy in ARSACS Research (BMBF), UCB Pharma GmbH
Investigators: Dr. Matthis Synofzik, Dr. Adam Vogel
(University of Melbourne) OPTIMED
Project leader: Prof. Dr. Daniela Berg
Slowing down disease progression in premanifest SCA: Funding institution: Federal Ministry for Economic Affairs
a piloting interventional exergame trial (SlowSCA) and Energy
Investigators: Dr. Matthis Synofzik, Dr. Winfried Ilg
Cerebral networks for gait and balance in the prodromal
EN-ETPKU: multicenter investigational study on neuro- phase of Parkinson’s disease: An fMRI study
degenerative aspects in patients with phenylketonuria Project leader: Prof. Dr. Daniela Berg
Investigators: Dr. Andrea Pilotto Funding institution: Interdisciplinary Center for Clinical
Research – IZKF-Promotionskolleg, University of Tübingen
NIC-PD
Project leader: Prof. Dr. Daniela Berg
Funding institution: Philipps-University Marburg
Promesa Study
Project leader: Prof. Dr. Daniela Berg
Funding institution: Ludwig-Maximilians-University Munich
dPV Research Grant “Cognitive control as a key function of
urinary incontinence in patients with MP”
Project leader: Prof. Dr. Daniela Berg
Funding institution: dPV – Deutsche Parkinsonvereinigung e.V.
Fox Trial Finder 2014
Project leader: Prof. Dr. Daniela Berg
Funding institution: Michael J. Fox Foundation for
Parkinson’s Research
24ANNUAL REPORT 2015
PPMI – The Parkinson’s Progression Initiative MJFF Research Grant 2013 – Influence of immune subtypes
Project leader: Prof. Dr. Daniela Berg on the LRRK2 phenotype
Funding institution: Michael J. Fox Foundation for Project leader: Prof. Dr. Daniela Berg, Prof. Dr. Walter Maetzler
Parkinson’s Research (MJFF) Funding institution: Michael J. Fox Foundation for
Parkinson’s Research (MJFF)
PPMI – Amendment: Genetic PPMI
Project leader: Prof. Dr. Daniela Berg Research Grant “Pathophysiological mechanisms of
Funding institution: Michael J. Fox Foundation for prodromal motor changes in individuals at risk
Parkinson’s Research (MJFF) for Parkinson’s disease”
Project leader: Prof. Dr. Daniela Berg
PPMI Amendment – Cognitive categorization assessment Funding institution: International Parkinson’s Fond
Project leader: Prof. Dr. Daniela Berg
Funding institution: Michael J. Fox Foundation for DAT-Imaging in LRRK2 gene carriers
Parkinson’s Research (MJFF) Project leader: Prof. Dr. Daniela Berg
Funding institution: Institute of Neurodegenerative
PPMI Amendment – Additional PD subjects Disorders, New Haven
Project leader: Prof. Dr. Daniela Berg
Funding institution: Michael J. Fox Foundation for Progression markers in the suspected premotor phase and
Parkinson’s Research (MJFF) early Parkinson’s disease (Amendment)
Project leader: Prof. Dr. Daniela Berg
Inclusion of Resting State MRI: A Parkinson’s Progression Funding institution: Janssen Pharmaceutica NV
Markers Initiative (PPMI) Substudy
Project leader: Prof. Dr. Daniela Berg PMPP – Amendment 4
Funding institution: Michael J. Fox Foundation for Project leader: Prof. Dr. Daniela Berg
Parkinson’s Research (MJFF) Funding institution: Janssen Pharmaceutica NV
P-PPMI – Prodromal subjects Observational study in non-demented patients with
Project leader: Prof. Dr. Daniela Berg Parkinson’s disease with lowered A-beta1-42 CFS levels
Funding institution: Michael J. Fox Foundation for Project leader: Prof. Dr. Daniela Berg, Prof. Dr. Walter Mätzler
Parkinson’s Research (MJFF) Funding institution: Janssen Pharmaceutica NV
Subaward agreement: Cognition biomarkers Kyowa-Study 6002-14
Project leader: Prof. Dr. Daniela Berg Project leader: Prof. Dr. Daniela Berg
Funding institution: Mayo Clinic, Michael J. Fox Foundation Funding institution: Kyowa Hakko Kirin Pharma
for Parkinson’s Research (MJFF)
NIS-Azilect
MJFF Research Grant 2011: Gait and motor symptoms Project leader: Prof. Dr. Daniela Berg
in healthy asymptomatic relatives of patients with PD Funding institution: TEVA Pharma GmbH
carriers of mutations in the LRRK2 gene
Project leader: Prof. Dr. Daniela Berg Agreement for a non-product related investigator
Funding institution: Michael J. Fox Foundation for initiated study
Parkinson’s Research (MJFF) Project leader: Prof. Dr. Daniela Berg
Funding institution: UCB
Subaward agreement: Penetrance of LRRK2
in the MJFF LRRK2 consortium Studie PD0013-Neupart
Project leader: Prof. Dr. Daniela Berg Project leader: Prof. Dr. Daniela Berg
Funding institution: University of Columbia, Funding institution: UCB Biosciences GmbH
Michael J. Fox Foundation for Parkinson’s Research (MJFF)
25Department of Neurodegenerative Diseases
Third-Party Funding Assessing the role of LRRK2 in sporadic PD pathology using
iPSC-derived dopaminergic neurons
Project leader: Prof. Dr. Thomas Gasser, Dr. Jared Sterneckert
ONGOING GRANTS (MPI), Dr. Christian Johannes Gloeckner (Eberhard Karls
University Tübingen)
Tumorigenesis in LRRK2 associated Parkinson’s disease Funding institution: Michael J. Fox Foundation for
Project leader: Prof. Rachel Saunders-Pullman, Parkinson’s Research (MJFF)
Dr. Saskia Biskup
Funding institution: Michael J. Fox Foundation for Investigation of molecular and cellular functions of TDP-
Parkinson’s Research 43 and FUS, pathorelevant proteins in frontotemporal
dementias (FTD) and amyotrophic lateral sclerosis (ALS)
Monocyte monitoring in LRRK2 associated Parkinson’s Project leader: Prof. Dr. Philipp Kahle
disease Funding institution: German Research Foundation (DFG)
Project leader: Prof. Dr. Thomas Gasser, Dr. Saskia Biskup
Funding institution: Michael J. Fox Foundation for Competence Net Degenerative Dementias &
Parkinson’s Research Frontotemporal Dementias
Project leader: Prof. Dr. Philipp Kahle
Functional proteomics of mutant LRRK2 Funding institution: Federal Ministry of Education and
induced Parkinson’s diesase Research (BMBF)
Project leader: Prof. Dr. Thomas Gasser,
Dr. Jared Sterneckert (MPI) Virtual Institute: RNA dysmetabolism in ALS and FTD
Funding institution: German Research Foundation (DFG) Project leader: Prof. Dr. Philipp Kahle
Funding institution: German Center for Neurodegenerative
Mitochondrial endophenotypes of PD (Mito-PD) Diseases (DZNE)
Project leader: Prof. Dr. Thomas Gasser (coordinator),
Prof. Dr. Rejko Krüger, Prof. Dr. Daniela Berg Intersite Project: Compound screen to correct mitochondrial
Funding institution: Federal Ministry of Education and phanotypes in recessive Parkinson’s disease
Research (BMBF) Project leader: Prof. Dr. Philipp Kahle
Funding institution: German Center for Neurodegenerative
Comprehensive unbiased risk factor assessment for genetics Diseases (DZNE)
and environment in Parkinson’s disease (COURAGE-PD)
Project leader: Prof. Dr. Thomas Gasser (coordinator), Mitochondria in neurodegeneration and ageing – translating
Prof. Dr. Rejko Krüger impaired mitochondrial dynamics to novel therapeutic
Funding institution: Federal Ministry of Education and strategies
Research (BMBF) Project Leader: Prof. Dr. Rejko Krüger, Prof. Dr. Philipp Kahle
Funding Institution: German Center for Neurodegenerative
Multimodal imaging of rare synucleinopathies (MultISyn) Diseases (DZNE)
Project leader: Prof. Dr. Thomas Gasser (coordinator)
Funding institution: EU Assessment of LRRK2 kinase activity in
peripheral blood cells
Protein interaction network analysis and pathway Project leader: Prof. Dr. Thomas Gasser, Prof. Dr. Philipp Kahle,
modeling for LRRK2 Dr. Kathrin Brockmann
Project leader: Prof. Dr. Thomas Gasser, Dr. Jared Sterneckert Funding institution: Michael J. Fox Foundation for
(MPI), Dr. Christian Johannes Gloeckner (Eberhard Karls Parkinson’s Research (MJFF)
University Tübingen)
Funding institution: Michael J. Fox Foundation for Investigation of ubiquitination and phosphorylation events
Parkinson’s Research (MJFF) in the process of mitophagy
Project leader: Dr. Sven Geisler
Funding institution: Fortüne Programme, University of
Tübingen
26Sie können auch lesen
